Skip to content

A prospective, randomized,open, multi-center clinical trial evaluating the efficiency and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)

A prospective, randomized,open, multi-center clinical trial evaluating the efficiency and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000002972
Enrollment
Unknown
Registered
2020-02-05
Start date
2020-02-06
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Sponsors

Beijing hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria of "Pneumonitis Diagnosis and Treatment Scheme for New Coronavirus Infection (Trial Version 5)"; (2) The classification was judged as common and severe type; (3) Having one or more symptoms of fever, cough and fatigue when entering the group; (4) The diagnosis time does not exceed 48 hours; (5) Aged >= 18 years.

Exclusion criteria

Exclusion criteria: (1) Immunodeficiency diseases, or those using immunosuppressive agents or glucocorticoids within the past 3 months; (2) Pregnancies, pregnant women and lactating women; (3) An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in this test); (4) Psychotic patients, or those without self-knowledge ability; (5) Patients whose estimated survival time does not exceed 48 hours from the start of screening; (6) Tracheal intubation and mechanical ventilation have been performed during screening; (7) Other problems that doctor's judgment is not suitable for the study.

Design outcomes

Primary

MeasureTime frame
Clinical symptom recovery rate;

Secondary

MeasureTime frame
Antipyretic time;clinical symptom disappearance time;improvement rate of chest CT;28-day survival rate;The disappearance time and disappearance rate of individual symptoms such as fever and cough;Time and rate of virus turning negative;Length of hospital stay;Severe conversion rate;Laboratory tests (leukocyte, lymphocyte count, neutrophil count, C-reactive protein, erythrocyte sedimentation rate, D-dimer improvement);

Countries

China

Contacts

Public ContactLiu Qingquan

Beijing hospital of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese and Western Medicine Hospital

Liuqingquan2003@126.com+86 010-52176520

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026